A systematic review and meta-analysis of the safety of anti-interleukin therapy in COVID-19
Objective. To evaluate safety of anti-interleukin drugs used as a pathogenetic therapy of COVID-19 as assessed by risks of infectious complications. Materials and Methods. A systematic review of publications related to safety assessment of anti-interleukin drugs recommended as pathogenetic thera...
Main Authors: | Gomon Yu.M., Kolbin A.S., Strizheletsky V.V., Ivanov I.G., Sultanova F.M., Balykina Yu.E. |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2022-06-01
|
Series: | Клиническая микробиология и антимикробная химиотерапия |
Subjects: | |
Online Access: | https://cmac-journal.ru/publication/2022/2/cmac-2022-t24-n2-p93/cmac-2022-t24-n2-p93.pdf |
Similar Items
-
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
by: Vishnu Eshwar, et al.
Published: (2022-11-01) -
Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis
by: O. V. Boyko, et al.
Published: (2019-03-01) -
CHANGES IN THE PARAMETERS OF BLOOD LIPIDS AND CYTOKINES IN PATIENTS WITH PRIMARY OSTEOARTHRITIS DURING TREATMENT WITH ARTHRA
by: E Yu Alexenko, et al.
Published: (2011-06-01) -
Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
by: Kunming Pan, et al.
Published: (2023-04-01) -
Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin
by: Yu. M. Gomon, et al.
Published: (2022-10-01)